---
document_datetime: 2025-12-29 09:59:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xagrid.html
document_name: xagrid.html
version: success
processing_time: 0.362736
conversion_datetime: 2025-12-30 09:09:23.436332
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xagrid

[RSS](/en/individual-human-medicine.xml/67028)

##### Authorised

This medicine is authorised for use in the European Union

anagrelide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Xagrid](#more-information-on-xagrid-854)
- [More information on Xagrid](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xagrid is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets in the blood). 'Essential' means that the disease has no obvious cause.

Xagrid is used when patients do not respond to or do not tolerate their current treatment, and when they are 'at risk' because of their age (over 60 years), very high platelet counts or previous clotting problems.

Xagrid contains the active substance anagrelide.

Expand section

Collapse section

## How is Xagrid used?

Xagrid can only be obtained with a prescription. Treatment should only be started by a doctor who has experience in the treatment of essential thrombocythaemia.

Xagrid is available as capsules (0.5 mg). The recommended starting dose is 1 capsule twice a day. The dose can then be increased every week by 1 capsule a day, until the patient's platelet count is below 600 million platelets per millilitre, and ideally between 150 and 400 million/ml (the usual level in healthy people).

The maximum recommended dose of Xagrid is 5 capsules at a time. For more information about using Xagrid, see the package leaflet or contact a doctor or a pharmacist.

## How does Xagrid work?

In essential thrombocythaemia the bone marrow produces too many platelets. The active substance in Xagrid, anagrelide, blocks the development and growth of cells in the bone marrow called 'megakaryocytes', which produce platelets. This reduces the platelet count, helping to improve symptoms in patients with the disease.

## What benefits of Xagrid have been shown in studies?

Xagrid was effective in lowering platelet counts in four main studies involving patients with various diseases in which the bone marrow produces too many cells. Almost 3,000 of the patients in the studies had essential thrombocythaemia, with a platelet count of more than 600 million/ml. Most patients had previously received other medicines but could not continue with them. Xagrid was not compared with any other medicines. Patients were treated with Xagrid for up to five years. The main measure of effectiveness was the number of patients who had a 'complete response', when platelet counts fell either by at least 50% from the start of treatment or to below 600 million/ml.

In the largest study, 67% of the patients with essential thrombocythaemia (628 out of 934), and 66% of those who could not tolerate other treatments or whose condition did not respond to them (480 out of 725) had a complete response to Xagrid. In the other three studies, between 60 and 82% of patients had a complete response.

## What are the risks associated with Xagrid?

The most common side effect with Xagrid (which may affect more than 1 in 10 people) is headache. For the full list of all side effects of Xagrid, see the package leaflet.

Xagrid must not be used in patients with moderate or severe liver or kidney disease. For the full list of restrictions, see the package leaflet.

## Why is Xagrid authorised in the EU?

The European Medicines Agency decided that Xagrid's benefits are greater than its risks and recommended that it be given marketing authorisation.

Xagrid was originally authorised under 'exceptional circumstances'. This is because, as a result of the disease's rarity, it had not been possible to obtain full information about it. As the company has supplied the additional information requested, the 'exceptional circumstances' ended on 11/07/2018.

## What measures are being taken to ensure the safe and effective use of Xagrid?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xagrid have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xagrid are continuously monitored. Side effects reported with Xagrid are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xagrid

Xagrid received a marketing authorisation valid throughout the EU on 16 November 2004.

Xagrid : EPAR - Medicine overview

English (EN) (74.48 KB - PDF)

**First published:** 20/11/2009

**Last updated:** 02/08/2018

[View](/en/documents/overview/xagrid-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-380)

български (BG) (100.14 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/bg/documents/overview/xagrid-epar-medicine-overview_bg.pdf)

español (ES) (75.02 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/es/documents/overview/xagrid-epar-medicine-overview_es.pdf)

čeština (CS) (98.34 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/cs/documents/overview/xagrid-epar-medicine-overview_cs.pdf)

dansk (DA) (73 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/da/documents/overview/xagrid-epar-medicine-overview_da.pdf)

Deutsch (DE) (76.08 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/de/documents/overview/xagrid-epar-medicine-overview_de.pdf)

eesti keel (ET) (72.8 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/et/documents/overview/xagrid-epar-medicine-overview_et.pdf)

ελληνικά (EL) (103.24 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/el/documents/overview/xagrid-epar-medicine-overview_el.pdf)

français (FR) (75.65 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/fr/documents/overview/xagrid-epar-medicine-overview_fr.pdf)

hrvatski (HR) (95.63 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/hr/documents/overview/xagrid-epar-medicine-overview_hr.pdf)

italiano (IT) (73.58 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/it/documents/overview/xagrid-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (102.82 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/lv/documents/overview/xagrid-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (97.35 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/lt/documents/overview/xagrid-epar-medicine-overview_lt.pdf)

magyar (HU) (94.75 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/hu/documents/overview/xagrid-epar-medicine-overview_hu.pdf)

Malti (MT) (99.08 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/mt/documents/overview/xagrid-epar-medicine-overview_mt.pdf)

Nederlands (NL) (74.4 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/nl/documents/overview/xagrid-epar-medicine-overview_nl.pdf)

polski (PL) (97.69 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/pl/documents/overview/xagrid-epar-medicine-overview_pl.pdf)

português (PT) (74.94 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/pt/documents/overview/xagrid-epar-medicine-overview_pt.pdf)

română (RO) (102.13 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/ro/documents/overview/xagrid-epar-medicine-overview_ro.pdf)

slovenčina (SK) (97.51 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/sk/documents/overview/xagrid-epar-medicine-overview_sk.pdf)

slovenščina (SL) (92.06 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/sl/documents/overview/xagrid-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.08 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/fi/documents/overview/xagrid-epar-medicine-overview_fi.pdf)

svenska (SV) (73.51 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

02/08/2018

[View](/sv/documents/overview/xagrid-epar-medicine-overview_sv.pdf)

## Product information

Xagrid : EPAR - Product Information

English (EN) (211.59 KB - PDF)

**First published:** 20/11/2009

**Last updated:** 20/02/2023

[View](/en/documents/product-information/xagrid-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-722)

български (BG) (247.21 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/bg/documents/product-information/xagrid-epar-product-information_bg.pdf)

español (ES) (222.73 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/es/documents/product-information/xagrid-epar-product-information_es.pdf)

čeština (CS) (228.72 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/cs/documents/product-information/xagrid-epar-product-information_cs.pdf)

dansk (DA) (200.09 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/da/documents/product-information/xagrid-epar-product-information_da.pdf)

Deutsch (DE) (227.43 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/de/documents/product-information/xagrid-epar-product-information_de.pdf)

eesti keel (ET) (206.26 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/et/documents/product-information/xagrid-epar-product-information_et.pdf)

ελληνικά (EL) (242.77 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/el/documents/product-information/xagrid-epar-product-information_el.pdf)

français (FR) (225.65 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/fr/documents/product-information/xagrid-epar-product-information_fr.pdf)

hrvatski (HR) (224.06 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/hr/documents/product-information/xagrid-epar-product-information_hr.pdf)

íslenska (IS) (225.15 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/is/documents/product-information/xagrid-epar-product-information_is.pdf)

italiano (IT) (220.84 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/it/documents/product-information/xagrid-epar-product-information_it.pdf)

latviešu valoda (LV) (217.3 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/lv/documents/product-information/xagrid-epar-product-information_lv.pdf)

lietuvių kalba (LT) (218.1 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/lt/documents/product-information/xagrid-epar-product-information_lt.pdf)

magyar (HU) (234.35 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/hu/documents/product-information/xagrid-epar-product-information_hu.pdf)

Malti (MT) (248.67 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/mt/documents/product-information/xagrid-epar-product-information_mt.pdf)

Nederlands (NL) (219.27 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/nl/documents/product-information/xagrid-epar-product-information_nl.pdf)

norsk (NO) (221.66 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/no/documents/product-information/xagrid-epar-product-information_no.pdf)

polski (PL) (233.38 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/pl/documents/product-information/xagrid-epar-product-information_pl.pdf)

português (PT) (221.8 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/pt/documents/product-information/xagrid-epar-product-information_pt.pdf)

română (RO) (233.16 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/ro/documents/product-information/xagrid-epar-product-information_ro.pdf)

slovenčina (SK) (220.72 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/sk/documents/product-information/xagrid-epar-product-information_sk.pdf)

slovenščina (SL) (217.91 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/sl/documents/product-information/xagrid-epar-product-information_sl.pdf)

Suomi (FI) (215.6 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/fi/documents/product-information/xagrid-epar-product-information_fi.pdf)

svenska (SV) (218.54 KB - PDF)

**First published:**

20/11/2009

**Last updated:**

20/02/2023

[View](/sv/documents/product-information/xagrid-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0100/G 16/02/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xagrid : EPAR - All Authorised presentations

English (EN) (58.56 KB - PDF)

**First published:** 24/04/2007

**Last updated:** 24/04/2007

[View](/en/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-613)

български (BG) (91.66 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/bg/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_bg.pdf)

español (ES) (56.68 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/es/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_es.pdf)

čeština (CS) (77.89 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/cs/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (59.21 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/da/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.78 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/de/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (58.53 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/et/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (74.85 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/el/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_el.pdf)

français (FR) (58.15 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/fr/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (86.25 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/hr/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (59.19 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/is/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_is.pdf)

italiano (IT) (56.21 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/it/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (79.56 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/lv/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (78.15 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/lt/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (78.29 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/hu/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (91.55 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/mt/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (57.89 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/nl/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (59.04 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/no/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_no.pdf)

polski (PL) (84.48 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/pl/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_pl.pdf)

português (PT) (56.24 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/pt/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_pt.pdf)

română (RO) (88.42 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/ro/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (79.26 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/sk/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (68.55 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/sl/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (57.64 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/fi/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (58.35 KB - PDF)

**First published:**

24/04/2007

**Last updated:**

24/04/2007

[View](/sv/documents/all-authorised-presentations/xagrid-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xagrid Active substance anagrelide International non-proprietary name (INN) or common name anagrelide Therapeutic area (MeSH) Thrombocythemia, Essential Anatomical therapeutic chemical (ATC) code L01XX35

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Xagrid is indicated for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

**An at-risk patient**

An at-risk ET is defined by one or more of the following features:

- &gt;60 years of age or;
- a platelet count &gt;1000 x 10 9 /l or;
- a history of thrombohaemorrhagic events.

## Authorisation details

EMA product number EMEA/H/C/000480 Marketing authorisation holder

Takeda Pharmaceuticals International AG Ireland

Branch Block 2 Miesian Plaza 50 -58 Baggot Street Lower Dublin 2 D02 HW68 Ireland

Marketing authorisation issued 15/11/2004 Revision 40

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xagrid : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (255.61 KB - PDF)

**First published:** 20/11/2009

**Last updated:** 20/02/2023

[View](/en/documents/procedural-steps-after/xagrid-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Xagrid-H-C-PSUSA-00000208-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/454299/2017

English (EN) (67.41 KB - PDF)

**First published:** 18/07/2017

**Last updated:** 18/07/2017

[View](/en/documents/scientific-conclusion/xagrid-h-c-psusa-00000208-201609-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Xagrid-H-C-480-P46-0055 : EPAR - Assessment Report

Adopted

Reference Number: EMA/791522/2016

English (EN) (625.02 KB - PDF)

**First published:** 25/11/2016

**Last updated:** 25/11/2016

[View](/en/documents/variation-report/xagrid-h-c-480-p46-0055-epar-assessment-report_en.pdf)

Xagrid-H-C-480-II-0059: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/697040/2014

English (EN) (8.28 MB - PDF)

**First published:** 23/12/2014

**Last updated:** 23/12/2014

[View](/en/documents/variation-report/xagrid-h-c-480-ii-0059-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Xagrid : EPAR - Scientific Discussion

English (EN) (405.11 KB - PDF)

**First published:** 24/04/2007

**Last updated:** 24/04/2007

[View](/en/documents/scientific-discussion/xagrid-epar-scientific-discussion_en.pdf)

Xagrid : EPAR - Procedural steps taken before authorisation

English (EN) (114.5 KB - PDF)

**First published:** 24/04/2007

**Last updated:** 24/04/2007

[View](/en/documents/procedural-steps/xagrid-epar-procedural-steps-taken-authorisation_en.pdf)

#### More information on Xagrid

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu300010) on 29 December 2000. Xagrid was withdrawn from the Community register of orphan medicinal products in November 2016 at the end of the 12-year period of market exclusivity.

#### More information on Xagrid

- [EMEA-000720-PIP01-09-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000720-pip01-09-m02)
- [Xagrid - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/xagrid)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/02/2023

## Share this page

[Back to top](#main-content)